Treatment of Alzheimer's Disease With CX516 (Ampalex)
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
Glutamate is an amino acid released by brain cells that acts to excite other cells. Glutamate
attaches to special sites on cells called AMPA (alpha-amino-2,3-dihydro-5 methyl
3-oxo-4-isoxazolepropanoic acid) receptors. The brain cells responsible for releasing
glutamate are damaged in Alzheimer's disease and other conditions affecting thinking and
reasoning.
Researchers would like to see if giving patients a drug that attaches to AMPA receptors
improves the symptoms of Alzheimer's disease.
CX516 (Ampalex) is a test drug that affects the AMPA receptors. This study will investigate
the effectiveness and safety of CX516 on patients with Alzheimer's disease.
Patients will be given capsules of CX516 or placebo (sugar pill that neither harms nor helps)
for up to 16 weeks in different amounts. The effectiveness of the drug will be measured by
neurological tests. Safety will be monitored by frequent check-ups and lab examinations.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Neurological Disorders and Stroke (NINDS)